Eli Lilly and Company Q2 Earnings Call Highlights
Kort samengevat
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Yahoo Finance.
Lees het volledige bericht ↗